Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunotherapy. 2010 Jul;2(4):551-60. doi: 10.2217/imt.10.32.

Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.

Author information

  • 1Department of Dermatology, Leicester Royal Infirmary, Leicester LE1 5WW, UK. anton@alexandroff.org

Abstract

The concept of using Mycobacterium for cancer treatment goes back to the 19th Century. Today, bacillus Calmette-Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that is arguably superior to intravesical chemotherapy for superficial disease and is commonly used as the first-line adjuvant treatment. Much has been learnt about the effects of BCG on bladder cancer and the immune system, but deeper understanding is required in order to improve its efficacy further, to be able to reliably predict responders and ultimately to adapt this most successful form of cancer immunotherapy for the treatment of other malignancies. This article summarizes the current understanding of BCG cancer immunotherapy mechanisms and discusses possible future developments.

PMID:
20636008
DOI:
10.2217/imt.10.32
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center